Literature DB >> 8784610

Interlaboratory comparison of sequence-specific PCR and ligase detection reaction to detect a human immunodeficiency virus type 1 drug resistance mutation. The AIDS Clinical Trials Group Virology Committee Drug Resistance Working Group.

R W Shafer1, M A Winters, D L Mayers, A J Japour, D R Kuritzkes, O S Weislow, F White, A Erice, K J Sannerud, A Iversen, F Pena, D Dimitrov, L M Frenkel, P S Reichelderfer.   

Abstract

Sequence-specific PCR was used in six laboratories and a ligase detection reaction was used in one laboratory to detect the zidovudine-resistance mutation at codon 215 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase DNA. The genotypes of 27 different clinical samples, including cultured HIV-1 isolates, peripheral blood mononuclear cells, and plasma, were correctly identified by 140 of 154 (91%) assays. The sensitivity for detecting a mutation was 96% for HIV-1 reverse transcriptase DNA clone mixtures containing 30% mutant DNA and 62% for mixtures containing 6% mutant DNA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8784610      PMCID: PMC229135     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

Review 1.  Resistance of human immunodeficiency virus type 1 to antiretroviral agents: a review.

Authors:  A Erice; H H Balfour
Journal:  Clin Infect Dis       Date:  1994-02       Impact factor: 9.079

Review 2.  HIV virology for clinical trials.

Authors:  R W Shafer; T C Merigan
Journal:  AIDS       Date:  1995       Impact factor: 4.177

3.  Nonisotopic hybridization assay for determination of relative amounts of genotypic human immunodeficiency virus type 1 zidovudine resistance.

Authors:  P S Eastman; E Boyer; L Mole; J Kolberg; M Urdea; M Holodniy
Journal:  J Clin Microbiol       Date:  1995-10       Impact factor: 5.948

4.  Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

Authors:  M H St Clair; J L Martin; G Tudor-Williams; M C Bach; C L Vavro; D M King; P Kellam; S D Kemp; B A Larder
Journal:  Science       Date:  1991-09-27       Impact factor: 47.728

5.  Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes.

Authors:  B A Larder; P Kellam; S D Kemp
Journal:  AIDS       Date:  1991-02       Impact factor: 4.177

6.  Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine.

Authors:  L M Frenkel; L E Wagner; S M Atwood; T J Cummins; S Dewhurst
Journal:  J Clin Microbiol       Date:  1995-02       Impact factor: 5.948

7.  Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group.

Authors:  R T D'Aquila; V A Johnson; S L Welles; A J Japour; D R Kuritzkes; V DeGruttola; P S Reichelderfer; R W Coombs; C S Crumpacker; J O Kahn; D D Richman
Journal:  Ann Intern Med       Date:  1995-03-15       Impact factor: 25.391

8.  The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA.

Authors:  S Kaye; E Comber; M Tenant-Flowers; C Loveday
Journal:  AIDS Res Hum Retroviruses       Date:  1995-10       Impact factor: 2.205

9.  Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

Authors:  R Schuurman; M Nijhuis; R van Leeuwen; P Schipper; D de Jong; P Collis; S A Danner; J Mulder; C Loveday; C Christopherson
Journal:  J Infect Dis       Date:  1995-06       Impact factor: 5.226

10.  Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.

Authors:  A J Japour; S Welles; R T D'Aquila; V A Johnson; D D Richman; R W Coombs; P S Reichelderfer; J O Kahn; C S Crumpacker; D R Kuritzkes
Journal:  J Infect Dis       Date:  1995-05       Impact factor: 5.226

View more
  3 in total

1.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

2.  Comparison of QIAamp HCV kit spin columns, silica beads, and phenol-chloroform for recovering human immunodeficiency virus type 1 RNA from plasma.

Authors:  R W Shafer; D J Levee; M A Winters; K L Richmond; D Huang; T C Merigan
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

3.  Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay.

Authors:  Amit Kapoor; Morris Jones; R W Shafer; Soo-Yon Rhee; Powel Kazanjian; Eric L Delwart
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.